320337-48-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline is used as a potential therapeutic agent for the treatment of various types of cancer. Its unique molecular structure allows it to target specific cellular pathways and receptors, making it a promising candidate for the development of targeted cancer therapies.
Used in Drug Delivery Systems:
In the field of drug delivery, 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline can be employed as a component in the design of novel drug delivery systems. Its structural properties may enable the development of targeted drug carriers, improving the bioavailability and therapeutic efficacy of various pharmaceutical compounds.
Used in Chemical Research:
4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline can also be utilized in chemical research as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique functional groups and structural features make it a valuable tool for exploring new chemical reactions and developing innovative synthetic strategies.
Used in Material Science:
4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline may find applications in the field of material science, particularly in the development of new materials with specific properties. Its structural features could be exploited to create materials with tailored characteristics, such as improved stability, enhanced reactivity, or unique optical properties.

Upstream product

• 231278-84-5 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde 
• 903597-10-4 N’-(2-cyano-4-iodophenyl)-N,N-dimethyl formamidine 
• 1885-29-6 anthranilic acid nitrile 
• 132131-24-9 5-iodoanthranilonitrile 
• 320337-47-1 5-(4-(3-Chloro-4-(3-fluorobenzyloxy)-anilino)-7-fluoro-quinazolin-6-yl)-furan-2-carbaldehyde 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 619-08-9 2-chloro-4-nitrophenol 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 443882-99-3 3-chloro-4-(3-fluorobenzyloxy)nitrobenzene 
• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 

Downstream Products

• 944549-46-6 4-[3-chloro-4-(3-fluorobenzyloxy)-phenylamino]-6-(5-methane-sulfonyloxymethylene-furan-2-yl)-quinazoline 

Relevant academic research and scientific papers

Synthesis and in vitro biological evaluation of novel quinazoline derivatives

A series of novel 4-arylamino-6-(5-substituted furan-2-yl)quinazoline derivatives were designed, synthesized and evaluated on biological activities in vitro. Compound 2a, 3a and 3c exhibited highly anti-proliferation activities on all tested tumor cell lines including SW480, A549, A431 and NCI-H1975 cells. Especially, compound 2a not only exhibited strong anti-proliferation activities against the tumor cell lines which expressed wild type or mutant EGFRL858R/T790M, but also showed the most potent inhibitory activity toward wild type EGFR (IC50?=?5.06?nM). The result of docking with EGFR suggested the binding mode of 2a was similar to that of lapatinib. While Western-blot analyses showed 2a obviously inhibited the activation of EGFR, Akt and Erk1/2 in lung cancer cells at indicated concentration. It is believed that this work would be very useful for developing a new series of TKIs targeting EGFR.

QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF

The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti- tumor medicament.

Quinazoline Derivatives, Preparation Methods and Uses Thereof

The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament.

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino provided the best enzyme potency and cellular selectivity. Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy. The discovery of lapatinib emerged from this work.

Anilinoquinazolines as protein tyrosine kinase inhibitors

Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.